388 related articles for article (PubMed ID: 27587556)
61. Early interstitial lung disease in familial pulmonary fibrosis.
Rosas IO; Ren P; Avila NA; Chow CK; Franks TJ; Travis WD; McCoy JP; May RM; Wu HP; Nguyen DM; Arcos-Burgos M; MacDonald SD; Gochuico BR
Am J Respir Crit Care Med; 2007 Oct; 176(7):698-705. PubMed ID: 17641157
[TBL] [Abstract][Full Text] [Related]
62. Overexpression of IL-38 protein in anticancer drug-induced lung injury and acute exacerbation of idiopathic pulmonary fibrosis.
Tominaga M; Okamoto M; Kawayama T; Matsuoka M; Kaieda S; Sakazaki Y; Kinoshita T; Mori D; Inoue A; Hoshino T
Respir Investig; 2017 Sep; 55(5):293-299. PubMed ID: 28942884
[TBL] [Abstract][Full Text] [Related]
63. Increased circulating desmosine and age-dependent elastinolysis in idiopathic pulmonary fibrosis.
de Brouwer B; Drent M; van den Ouweland JMW; Wijnen PA; van Moorsel CHM; Bekers O; Grutters JC; White ES; Janssen R
Respir Res; 2018 Mar; 19(1):45. PubMed ID: 29558926
[TBL] [Abstract][Full Text] [Related]
64. Increased levels of prostaglandin E-major urinary metabolite (PGE-MUM) in chronic fibrosing interstitial pneumonia.
Horikiri T; Hara H; Saito N; Araya J; Takasaka N; Utsumi H; Yanagisawa H; Hashimoto M; Yoshii Y; Wakui H; Minagawa S; Ishikawa T; Shimizu K; Numata T; Arihiro S; Kaneko Y; Nakayama K; Matsuura T; Matsuura M; Fujiwara M; Okayasu I; Ito S; Kuwano K
Respir Med; 2017 Jan; 122():43-50. PubMed ID: 27993290
[TBL] [Abstract][Full Text] [Related]
65. Discovery and validation of extracellular/circulating microRNAs during idiopathic pulmonary fibrosis disease progression.
Yang G; Yang L; Wang W; Wang J; Wang J; Xu Z
Gene; 2015 May; 562(1):138-44. PubMed ID: 25725128
[TBL] [Abstract][Full Text] [Related]
66. Impact of idiopathic pulmonary fibrosis on advanced non-small cell lung cancer survival.
Kanaji N; Tadokoro A; Kita N; Murota M; Ishii T; Takagi T; Watanabe N; Tojo Y; Harada S; Hasui Y; Kadowaki N; Bandoh S
J Cancer Res Clin Oncol; 2016 Aug; 142(8):1855-65. PubMed ID: 27350261
[TBL] [Abstract][Full Text] [Related]
67. Clinical Research on Prognostic Evaluation of Subjects With IPF by Peripheral Blood Biomarkers, Quantitative Imaging Characteristics and Pulmonary Function Parameters.
Guo L; Yang Y; Liu F; Jiang C; Yang Y; Pu H; Li W; Zhong Z
Arch Bronconeumol (Engl Ed); 2020 Jun; 56(6):365-372. PubMed ID: 31740085
[TBL] [Abstract][Full Text] [Related]
68. The Combined Model of CX3CR1-Related Immune Infiltration Genes to Evaluate the Prognosis of Idiopathic Pulmonary Fibrosis.
Cai H; Chen S; Li X; Liu H; Zhang Y; Zhuang Q
Front Immunol; 2022; 13():837188. PubMed ID: 35222428
[TBL] [Abstract][Full Text] [Related]
69. CYFRA 21.1 in bronchoalveolar lavage of idiopathic pulmonary fibrosis patients.
Vercauteren IM; Verleden SE; McDonough JE; Vandermeulen E; Ruttens D; Lammertyn EJ; Bellon H; De Dycker E; Dooms C; Yserbyt J; Verleden GM; Vanaudenaerde BM; Wuyts WA
Exp Lung Res; 2015; 41(8):459-65. PubMed ID: 26381718
[TBL] [Abstract][Full Text] [Related]
70. Using hyperpolarized
Wang JM; Robertson SH; Wang Z; He M; Virgincar RS; Schrank GM; Smigla RM; O'Riordan TG; Sundy J; Ebner L; Rackley CR; McAdams P; Driehuys B
Thorax; 2018 Jan; 73(1):21-28. PubMed ID: 28860333
[TBL] [Abstract][Full Text] [Related]
71. Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis.
Huang Y; Ma SF; Espindola MS; Vij R; Oldham JM; Huffnagle GB; Erb-Downward JR; Flaherty KR; Moore BB; White ES; Zhou T; Li J; Lussier YA; Han MK; Kaminski N; Garcia JGN; Hogaboam CM; Martinez FJ; Noth I;
Am J Respir Crit Care Med; 2017 Jul; 196(2):208-219. PubMed ID: 28157391
[TBL] [Abstract][Full Text] [Related]
72. Innate immunity proteins in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.
Tsoumakidou M; Bouloukaki I; Thimaki K; Tzanakis N; Siafakas NM
Exp Lung Res; 2010 Aug; 36(6):373-80. PubMed ID: 20653472
[TBL] [Abstract][Full Text] [Related]
73. Normal ex vivo mesenchymal stem cell function combined with abnormal immune profiles sets the stage for informative cell therapy trials in idiopathic pulmonary fibrosis patients.
Atanasova E; Milosevic D; Bornschlegl S; Krucker KP; Jacob EK; Carmona Porquera EM; Anderson DK; Egan AM; Limper AH; Dietz AB
Stem Cell Res Ther; 2022 Jan; 13(1):45. PubMed ID: 35101101
[TBL] [Abstract][Full Text] [Related]
74. Systemic immune cell activation in a subgroup of patients with idiopathic pulmonary fibrosis.
Homolka J; Ziegenhagen MW; Gaede KI; Entzian P; Zissel G; Müller-Quernheim J
Respiration; 2003; 70(3):262-9. PubMed ID: 12915745
[TBL] [Abstract][Full Text] [Related]
75. Practical management of Idiopathic Pulmonary Fibrosis.
Kishaba T
Sarcoidosis Vasc Diffuse Lung Dis; 2015 Jul; 32(2):90-8. PubMed ID: 26278687
[TBL] [Abstract][Full Text] [Related]
76. Matrix metalloproteinase-10: a novel biomarker for idiopathic pulmonary fibrosis.
Sokai A; Handa T; Tanizawa K; Oga T; Uno K; Tsuruyama T; Kubo T; Ikezoe K; Nakatsuka Y; Tanimura K; Muro S; Hirai T; Nagai S; Chin K; Mishima M
Respir Res; 2015 Sep; 16():120. PubMed ID: 26415518
[TBL] [Abstract][Full Text] [Related]
77. CA 19-9 serum levels in patients with end-stage idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs): Correlation with functional decline.
Balestro E; Castelli G; Bernardinello N; Cocconcelli E; Biondini D; Fracasso F; Rea F; Saetta M; Baraldo S; Spagnolo P
Chron Respir Dis; 2020; 17():1479973120958428. PubMed ID: 32969271
[TBL] [Abstract][Full Text] [Related]
78. Arterial Carboxyhemoglobin Measurement Is Useful for Evaluating Pulmonary Inflammation in Subjects with Interstitial Lung Disease.
Hara Y; Shinkai M; Kanoh S; Fujikura Y; K Rubin B; Kawana A; Kaneko T
Intern Med; 2017; 56(6):621-626. PubMed ID: 28321059
[TBL] [Abstract][Full Text] [Related]
79. A functional genomic model for predicting prognosis in idiopathic pulmonary fibrosis.
Huang Y; Ma SF; Vij R; Oldham JM; Herazo-Maya J; Broderick SM; Strek ME; White SR; Hogarth DK; Sandbo NK; Lussier YA; Gibson KF; Kaminski N; Garcia JG; Noth I
BMC Pulm Med; 2015 Nov; 15():147. PubMed ID: 26589497
[TBL] [Abstract][Full Text] [Related]
80. S100A9 in BALF is a candidate biomarker of idiopathic pulmonary fibrosis.
Hara A; Sakamoto N; Ishimatsu Y; Kakugawa T; Nakashima S; Hara S; Adachi M; Fujita H; Mukae H; Kohno S
Respir Med; 2012 Apr; 106(4):571-80. PubMed ID: 22209187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
